|
(wn)ÄÚÁ |
ÀÇ¾à ¾ÈÀü¼º °ü¸®ÀÚ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
04.09 |
|
|
Çì´Ï¾Ø¸ÓÄÚÀÌ |
Pharmacovigilance (MI) Specialist / Regulatory Affairs
¼¿ï °³²±¸, ¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
03.14 |
|
|
³×¸ðÆÄÆ®³ÊÁîHRG |
¿Ü±¹°è Á¦¾àȸ»ç Medical advisor (ÀÌ»ç±Þ)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
10.29 |
|
|
ÁÖ½Äȸ»ç ÀÎÅÚ¸®Àü½ºÄÚ¸®¾Æ |
[¿Ü±¹°èÁ¦¾à»ç] CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
07.07 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Diagnostics Manager(Oncology)/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
11.04 |
|
|
Ä¿¸®¾î¶óÀÌÁî |
[ÇìµåÇåÆà - ¿ì·® ¹ÙÀÌ¿À/Á¦¾à ȸ»ç] °ü¸®¾à»ç ä¿ë
°æ±â ¾È»ê½Ã ´Ü¿ø±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
06.27 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
Áß¼Òº¥ÃÄ»ç»ç Á¦Á¶°ü¸®¾à»ç(°úÀå~ÀÌ»ç±Þ)
ÃæºÏ û¿ø±º | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
02.17 |
|
|
(ÁÖ)ÇÇÇÃÄɾî½áÄ¡ |
Pharmacist -¿Ü±¹°èÁ¦¾à»ç
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
6³â¡è |
ä¿ë½Ã |
07.13 |
|
|
ÇdzÊŬ½áÄ¡ |
[ RA´ã´ç ¾à»ç, ÃÑ°æ·Â 6-12³â - ±Û·Î¹ú 1À§ Á¦¾à»ç ]
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
6³â¡è |
ä¿ë½Ã |
07.27 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
»ç¾÷°³¹ß½ÇÆÀÀå(Business Development Team Leader)/±¹³»À¯
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
¾à»ç/ÇѾà»ç |
7³â¡è |
ä¿ë½Ã |
09.13 |
|
|
¿Ü±¹°è Á¦¾à»ç |
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
7³â¡è |
ä¿ë½Ã |
12.24 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Clinical Project Leader/±¹³»À¯¸íÁ¦¾àȸ»ç
¼¿ï °³²±¸, ¼¿ï °³²±¸, ¼¿ï °³²±¸ | Çз¹«°ü |
¾à»ç/ÇѾà»ç |
7³â¡è |
ä¿ë½Ã |
09.24 |
|
|
¹Ý¼®½áÄ¡(ÁÖ) |
Áß°ßÁ¦¾à»ç / Á¦Á¦¿¬±¸ÆÀÀå
Ãæ³² ¾Æ»ê½Ã | ´ëÇпø(¼®»ç) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
7³â¡è |
ä¿ë½Ã |
10.18 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Medical Team Manager/Èñ±ÍÁúȯFranchise(±¹³» »óÀ§±ÇÀÇ Á¦
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
7³â¡è |
ä¿ë½Ã |
01.13 |
|
|
(ÁÖ)¿¡ÄÚ½áÄ¡ |
¿Ü±¹°èÁ¦¾àȸ»ç/Local Trial Manager(ÀÓ»ó)
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
8³â¡è |
ä¿ë½Ã |
11.29 |
|